Screener / SEC EDGAR /CIK 0001609550 /10-K filed Feb 13, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Inspire Medical Systems, Inc. INSP

Compare with peers Embed
The 10-K against last year's

173 changes: 37 added, 28 removed, 105 reworded, 3 quiet changes

10-K Feb 13, 2026 vs Feb 10, 2025

10-K 0001609550-26-000016 (Feb 13, 2026) vs 10-K 0001609550-25-000011 (Feb 10, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

343 paragraphs · 29 new · 102 reworded · 17 gone · 10-K Feb 13, 2026 against Feb 10, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 156 · 47% changed Every version of it
In addition, the impacts of climate-related events on the global economy and our industry are rapidly evolving. Physical impacts of climate-related events (including but not limited to floods, droughts, more frequent and/or intense storms and wildfires), or chronic changes (such as droughts, heat waves or sea level changes) in climate patterns can adversely impact our operations, as well as the operations of our suppliers and customers. Our facilities and offices may be adversely impacted by natural disasters, including those intensified by climate change. Our locations, and those of our customers and suppliers, can be disrupted by droughts, extreme temperatures, fires, flooding and other climate change-related risks, as well as earthquakes, actions by utility providers, and other catastrophic events such as an actual or threatened public health emergency. If a catastrophic event occurs at or near any of our offices, or utility providers or public health officials take certain actions (e.g., shut off power to our facilities), our operations may be interrupted, which could adversely impact our business and results of operations. If a catastrophic event impacts a significant number of our suppliers or customers, or our customers' ability to perform DISE procedures, implant our Inspire system, or perform related procedures, our business and results of operations could be adversely impacted. For example, in the wake of recent hurricanes, our customers experienced delays and shortages of certain products that were necessary to complete DISE procedures and the implant procedure for our Inspire system. These disruptions caused some customers to limit or postpone surgical procedures or elective procedures performed at their facilities, including DISE procedures and implantations of our Inspire system. Our customers have experienced similar disruptions as result of the recent wildfires in California. These disruptions have caused some customers to limit or postpone surgical procedures or elective procedures at their facilities, including DISE procedures and implantations of our Inspire system. Longer-term physical impacts may also result in changing consumer preferences, which may adversely impact demand for certain of our products. Transition impacts of climate-related events may subject us to increased regulations, reporting requirements, standards or expectations regarding the environmental impacts of our business. Failure to disclose accurate climate-related events information in a timely manner may also adversely affect our reputation, business, or financial performance.
Paragraph 238 · 46% changed Every version of it
Healthcare policy changes, including recently enacted Current and future healthcare reform legislation reforming or regulation may increase the U.S. healthcare system, difficulty and cost for us to commercialize our products and could harm our business, financial condition and results of operations.
Paragraph 9 · 46% changed Every version of it
•changes in coverage policies by third-party payors that affect the reimbursement of procedures using our products; products (as well as confusion about potential changes to reimbursement even where no formal change occurs and including any indirect impacts from any changes to provider and patient behavior);
Paragraph 268 · 44% changed Every version of it
Patient enrollment in clinical studies and completion of patient follow-up depend on many factors, including the size of the patient population, the nature of the study protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical study, patient compliance, competing clinical studies and clinicians’ and patients’ perceptions as to the potential advantages of the product being studied in relation to other available therapies, including any new treatments that may be approved for the indications we are investigating. For example, patients may be discouraged from enrolling in our clinical studies if the study protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and efficacy of a product candidate, or they may be persuaded to participate in contemporaneous clinical studies of a competitor’s product candidate. In addition, patients participating in our clinical studies may drop out before completion of the study or experience adverse medical events unrelated to our products. Delays in patient enrollment or failure of patients to continue to participate in a clinical study may delay commencement or completion of the clinical study, cause an increase in the costs of the clinical study and delays, or result in the failure of the clinical study.
Paragraph 58 · 43% changed Every version of it
On July 16, 2024, January 27, 2026, a stockholder derivative lawsuit was filed in the United States District Court for the Southern District of Minnesota, New York, purportedly on behalf of Inspire against certain of our present and former executive officers and directors against all current members of the Board of Directors and Inspire (as a nominal defendant), captioned Lawrence Hollin Korte v. Herbert, Herbert., et al., Court File Case No. 0:24-cv-02716 (the “Hollin Lawsuit”). 1:26‑cv‑680 (S.D.N.Y.). The Hollin Lawsuit arose lawsuit arises out of the same subject matter as the City of Hollywood Indiana PRS Lawsuit described above and alleged alleges the following claims under common law and claims: (1) Section 14(a) of the Exchange Act: (1) Act and Rule 14a-9 promulgated thereunder; (2) Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder; (3) Section 20(a) of the Exchange Act; (4) a common-law claim for breach of fiduciary duty; (2) (5) common-law aiding and abetting; (6) unjust enrichment; (3) and (7) waste of corporate assets; assets. The lawsuit seeks unspecified damages. The Company and (4) as the individual defendants intend to vigorously defend against the officer defendants, contribution under Sections 10(b) and 21D of the Exchange Act. The lawsuit sought unspecified damages. On September 5, 2024, counsel for Mr. Hollin filed a motion for voluntary dismissal of the Hollin Lawsuit, which motion remains pending. action.
Paragraph 219 · 43% changed Every version of it
There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims and physician transparency laws. Our business practices and relationships with providers are subject to scrutiny under these laws. The healthcare laws and regulations that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and civil monetary penalties laws, including the federal civil False Claims Act, the federal Civil Monetary Penalties Law, federal criminal fraud and abuse laws under HIPAA, analogous state and foreign law equivalents of each of the foregoing. See Part I, Item 1. "Business — Government Regulation."
Paragraph 40 · 43% changed Every version of it
reimbursement for procedures using our products exists among third-party payors. Therefore, coverage and reimbursement for procedures using our products can differ significantly from payor to payor. Payors continually review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and procedures. There can be no assurance that third-party payor policies will provide full or meaningful coverage for procedures in which our products are used. If we are not successful in reversing existing non-coverage policies, or if third-party payors that currently cover or reimburse our products and related procedures reverse or limit their coverage in the future, or if other third-party payors issue similar policies, this could have a material adverse effect on our business. Overall, new products and changes in the industry can drive changes to (or a lack of clarity for) reimbursement. Our own products have been billed under different codes and reimbursement approaches throughout our history. Most recently, since the rollout of Inspire V in 2025, there has been confusion and changes (from both government healthcare programs and other payors and parties involved in setting reimbursement and coding) around the appropriate reimbursement and coding for our products that has the potential to adversely impact our revenues, business, financial condition and results of operations. For additional information, see Part I. Item a. "Business - Third-Party Reimbursement - Coding and Payment" and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Overview.”
Paragraph 295 · 39% changed Every version of it
Moreover, we may become party to future adversarial proceedings regarding our patent portfolio or the patents of third parties. Such proceedings could include supplemental examination or contested post-grant proceedings such as review, reexamination, inter partes review, interference or derivation proceedings before the USPTO and challenges in U.S. District Court. Patents may be subjected to opposition, post-grant review or comparable proceedings lodged in various foreign, both national and regional, patent offices. The legal threshold for initiating litigation or contested proceedings may be low, so that even lawsuits or proceedings with a low probability of success might be initiated. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. We may also occasionally use these proceedings to challenge the patent rights of others. We cannot be certain that any particular challenge will be successful in limiting or eliminating the challenged patent rights of the third party. In May 2025, we filed a lawsuit against Nyxoah in the United States District Court for the District of Delaware, alleging that Nyxoah's Genio product infringes on certain of our U.S. patents related to neurostimulation therapy for obstructive sleep apnea. We are seeking a judgment of patent infringement and relief for such infringement, including monetary damages such as lost profits. Nyxoah has denied infringement and has asserted counterclaims seeking declaratory judgments of invalidity and non‑infringement. Nyxoah subsequently filed a lawsuit in September 2025 against us in the United States District Court for the District of Delaware alleging that our Inspire IV and Inspire V implantable neurostimulators infringe certain of Nyxoah’s patents. Additionally, in December 2025, Nyxoah brought suit against us and our wholly-owned subsidiary, Inspire Medical Systems Europe GmbH in the Unified Patent Court, Munich Division, alleging that the Inspire IV implantable neurostimulator infringes a patent owned by Nyxoah. Also in December 2025, Nyxoah filed three (3) petitions with the United States Patent Trial and Appeal Board seeking inter partes review (IPR) of the three patents asserted by Inspire in the lawsuit.

MD&A

70 paragraphs · 8 new · 40 reworded · 11 gone · 10-K Feb 13, 2026 against Feb 10, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 34 · 42% changed
Gross margin was 85.4% for the year ended December 31, 2025 compared to 84.7% for the year ended December 31, 2024 compared to 84.5% for the year ended December 31, 2023. 2024. This increase was primarily due to increased sales volume as well as increased sales mix of the Inspire V system, which is less expensive to manufacture and manufacturing efficiencies. therefore has a higher gross margin than the Inspire IV system, partially offset by the excess inventory component charge discussed above.
Paragraph 56 · 40% changed
A discussion of recent accounting pronouncements is included in (1) See Note 2 3 to our financial statements contained Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
Paragraph 59 · 40% changed
The following table presents a summary of our cash flow for the periods indicated:Year Ended December 31, 2024 2023 (in thousands) Net cash provided by (used in): Operating activities $ 130,246 $ 24,653 Investing activities (113,122) (294,822) Financing activities (52,393) 13,950 Effect of exchange rate on cash (118) 164 Decrease in cash and cash equivalents $ (35,387) $ (256,055)
Paragraph 60 · 34% changed
Net cash provided by operating activities was $130.2 $117.0 million for 2024 2025 and consisted of net income of $53.5 $145.4 million, non-cash charges of $114.4 $58.9 million, and a decrease in net operating assets of $37.7 $87.4 million. The non-cash charges consisted primarily of stock-based compensation, which increased mainly as a result of the accelerated recognition of stock-based compensation expense for employees who are retirement eligible in accordance with implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement, and granting more equity awards to a greater number of employees as compared to the same prior year prior-year period. The remainder of the non-cash charges included accretion the recognition of investment discount due to higher investment balances, a deferred tax benefit, depreciation and amortization expense which increased with additional purchases of property and equipment, an impairment of a strategic investment, accretion of investment discount on our available-for-sale investments, a change in the benefit provision for estimated credit losses related primarily to accounts receivable with two healthcare systems, losses, and other non-cash expenses. other, net. Operating assets include inventories, which increased as supply chain constraints continued we continue to ease and build inventory on hand increased levels to support higher sales and the launch of our next generation Inspire system, V, and accounts receivable, which increased primarily due to the higher sales volume we typically experience late in the fourth quarter. which occurred during September 2025. Operating assets also include prepaid expenses and other current assets, assets which increased primarily due to miscellaneous receivables and interest income receivable on our higher investment balances. slightly. Operating liabilities include accrued expenses accounts payable, which increased primarily generally due to compensation the timing of vendor invoice payments, and personnel-related costs, and accounts payable. accrued expenses, which increased slightly.
Paragraph 29 · 33% changed
Other income, net consists primarily of interest and dividend income, minimal interest expense under our former credit facility, expense, the impacts of foreign currency transactions and remeasurements, and gains and losses on investments. investments, and an impairment charge related to a strategic investment.
Paragraph 43 · 32% changed
•a decrease of $14.8 $137.3 million in cash and cash equivalents and short-term available for sale investments primarily due to the ASR we entered in November 2024 $175.0 million of share repurchases made under our share repurchase programs, as well as inventory purchases and the purchase payment of long-term available-for-sale investments and inventory, taxes on net share settlements of equity awards, partially offset by proceeds from sales of the Inspire system, proceeds from the exercise of stock options, and interest and dividend income; income, and the increase in long-term available for sale investments;
Paragraph 28 · 32% changed
We expect SG&A expenses to continue to increase as we expand our commercial infrastructure to both drive and support our planned growth in revenue and as we increase our headcount and expand administrative personnel to support our growth and operations as a public company including finance, legal, and human resources personnel and information technology services. Additionally, we anticipate an increase in our stock-based compensation expense with grants of stock options, restricted stock units, performance stock units, and shares of our common stock purchased pursuant to our employee stock purchase plan.
Paragraph 31 · 32% changed
Revenue increased $178.0 million, or 28.5%, to $802.8 generated in the U.S. was $872.1 million for the year ended December 31, 2024 compared to 2025, an increase of $101.0 million, or 13.1%, over the year ended December 31, 2023. The increase was attributable to a $164.9 million increase in sales of our Inspire system 2024. Revenue growth in the U.S and an increase of $13.1 million outside of the U.S. Overall revenue growth was primarily due to increased market penetration in existing centers, expansion into new territories and centers, penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints. constraints and some patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A379 words changed in this paragraph; it is 40% similar to last year's version.
During 2023 and 2024, Since 2023, glucagon-like peptide 1 ("GLP-1s"), a class of drug indicated for diabetes and obesity, has continued to gain popularity as a weight-loss drug. In late 2024, Zepbound (tirzepatide), tirzepatide (marketed as Zepbound), a GLP-1 injection which was FDA approved for weight loss in 2023, was also FDA approved for treatment of OSA in patients with obesity and moderate to severe OSA. If GLP-1s are used to treat OSA in an indication for which Inspire therapy is approved, demand for our Inspire system for patients with that indication could be reduced. OSA is a multifactorial disease with many independent factors including age, gender, weight, and neck circumference. Inspire is designed to address anteroposterior antero-posterior airway collapse, also known as tongue base collapse. Additionally, In contrast, patients with a higher BMI are subject to a larger neck circumference and present predominantly with lateral-wall collapse. A combination of tongue base collapse and lateral wall collapse is identified as a complete concentric collapse of the upper airway. Inspire is contraindicated for complete concentric collapse. In April 2024, Eli Lilly and Company ("Lilly") published headline results from its SURMOUNT-OSA trial demonstrating a 50.7% reduction in Apnea-Hypopnea Index ("AHI") for patients in the therapy arm of the study using tirzepatide, a GLP-1 injection. Subsequently, in June 2024, Lilly published additional results from its SURMOUNT-OSA trial demonstrating 43% of participants treated with tirzepatide at the highest dose met criteria for disease resolution. In this context, "disease resolution" means achieving an AHI of fewer than 5 events per hour, or an AHI of 5 to 14 events per hour and an Epworth Sleepiness Scale ("ESS") score of ≤10. ESS is a standard questionnaire designed to assess excessive daytime sleepiness. Given a baseline AHI of 50.3, and based on these results, we believe that most patients enrolled in the study will continue to have residual moderate to severe OSA that will require treatment and fall within Inspire’s FDA-approved indication. While weight loss may help reduce a patient’s AHI and other OSA symptoms, numerous other studies have shown that weight loss alone will not resolve OSA for the vast majority of patients. We expect GLP-1s may help patients address their lateral wall collapse, making them a potential candidate for Inspire therapy to the extent they also have tongue base collapse. Based on our ongoing ADHERE patient registry, the average BMI of patients treated with Inspire therapy is 29 and the American Academy of Sleep Medicine guidelines recommend weight loss prior to surgery for patients with BMI over 35 and nonsurgical solutions for patients with BMI over 40. Therefore, we believe there is not a notable overlap between the Inspire patient population and the patient population being treated with GLP-1s today. While we cannot quantify the impact, we believe that there could be a benefit to our business as a result of GLP-1s reducing the BMI of our prospective patients and increasing the number of eligible patients for our Inspire therapy, although there can be no assurance of such benefit at this time.

Source: Item 7, 10-K 0001609550-26-000016 vs Item 7, 10-K 0001609550-25-000011

Risk Factors276 words changed in this paragraph; it is 32% similar to last year's version.
Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On December 22, 2023, we November 6, 2025, the City of Pontiac Reestablished General Employees’ Retirement System, on behalf of itself and other similarly situated investors, filed a putative securities class action in the United States District Court for the District of Minnesota against the Company and certain of our its executive officers were named in a putative class action lawsuit. officers, captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., Case No. 0:25‑cv‑04247‑PJS‑ECW (D. Minn.) (the “City of Pontiac Lawsuit”). The plaintiff filed an amended complaint on April 19, 2024, which alleges alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, amended (the “Exchange Act”), and Rule 10b-5, which 10b‑5 promulgated thereunder, based on purportedly materially false and misleading statements made between August 6, 2024, and August 4, 2025, regarding the launch of the Company’s Inspire V neurostimulator. The complaint further alleged violations relate to certain prior that when subsequent disclosures were made concerning issues with the Inspire V launch and the Company announced its third‑quarter fiscal 2025 results, the Company’s stock price declined, purportedly causing investor losses. On December 23, 2025, the plaintiff filed a Notice of Inspire about Voluntary Dismissal. On December 29, 2025, the effectiveness of a program intended to help certain customers establish independence in seeking prior authorization from payors for our Inspire therapy. The plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired Inspire common stock between May 3, 2023 and November 7, 2023. The plaintiff seeks damages and other relief, including attorneys' fees and costs. The defendants are vigorously defending this lawsuit. On June 28, 2024, the defendants moved to dismiss the amended complaint in its entirety. The motion case was argued in November 2024. administratively closed without prejudice.

Source: Item 1A, 10-K 0001609550-26-000016 vs Item 1A, 10-K 0001609550-25-000011

Legal Proceedings145 words changed in this paragraph; it is 51% similar to last year's version.
On July 16, 2024, January 27, 2026, a stockholder derivative lawsuit was filed in the United States District Court for the Southern District of Minnesota, New York, purportedly on behalf of Inspire against certain of our present and former executive officers and directors against all current members of the Board of Directors and Inspire (as a nominal defendant), captioned Lawrence Hollin Korte v. Herbert, Herbert., et al., Court File Case No. 0:24-cv-02716 (the “Hollin Lawsuit”). 1:26‑cv‑680 (S.D.N.Y.). The Hollin Lawsuit arose lawsuit arises out of the same subject matter as the City of Hollywood Indiana PRS Lawsuit described above and alleged alleges the following claims under common law and claims: (1) Section 14(a) of the Exchange Act: (1) Act and Rule 14a-9 promulgated thereunder; (2) Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder; (3) Section 20(a) of the Exchange Act; (4) a common-law claim for breach of fiduciary duty; (2) (5) common-law aiding and abetting; (6) unjust enrichment; (3) and (7) waste of corporate assets; assets. The lawsuit seeks unspecified damages. The Company and (4) as the individual defendants intend to vigorously defend against the officer defendants, contribution under Sections 10(b) and 21D of the Exchange Act. The lawsuit sought unspecified damages. On September 5, 2024, counsel for Mr. Hollin filed a motion for voluntary dismissal of the Hollin Lawsuit, which motion remains pending. action.

Source: Item 3, via Note 11 – Commitments and Contingencies, 10-K 0001609550-26-000016 vs Item 3, via Note 12 – Commitments and Contingencies, 10-K 0001609550-25-000011

Accounting Policies123 words changed in this paragraph; it is 66% similar to last year's version.
We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. As Prior to December 31, 2025, as we have historically incurred operating losses, we have recorded a full valuation allowance against our net deferred tax assets. We will continue to maintain As of December 31, 2025, we determined that it is more-likely-than-not that our federal and a full valuation allowance until the point at which we are more certain than not that the majority of state deferred tax assets will be realized. Therefore there As a result, we recorded a release of the valuation allowance associated with these deferred tax assets, which was due in part to achieving three years of cumulative taxable income and projected taxable income that is no provision for more than sufficient to realize our federal income taxes, but we do and a majority of state deferred tax assets. We record provision for current state a federal, state, and foreign taxes, tax provision, which includes a foreign tax reserve relating to uncertain tax positions. Our policy is to record interest and penalty expense related to

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001609550-26-000016 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001609550-25-000011

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of INSP's Risk Factors and MD&A, 10-K Feb 13, 2026 against 10-K Feb 10, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6, 2025, the City of Pontiac Reestablished General Employees’ Retirement System, on behalf of itself and other similarly situated investors, filed a putative securities class action in the United States District Court for the District of Minnesota against the Company and certain of its executive officers, captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., Case No. 0:25‑cv‑04247‑PJS‑ECW (D. Minn.) (the “City of Pontiac Lawsuit”). The complaint alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b‑5 promulgated thereunder, based on purportedly materially false and misleading statements made between August 6, 2024, and August 4, 2025, regarding the launch of the Company’s Inspire V neurostimulator. The complaint further alleged that when subsequent disclosures were made concerning issues with the Inspire V launch and the Company announced its third‑quarter fiscal 2025 results, the Company’s stock price declined, purportedly causing investor losses. On December 23, 2025, the plaintiff filed a Notice of Voluntary Dismissal. On December 29, 2025, the case was administratively closed without prejudice.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
On December 22, 2025, the Indiana Public Retirement System, on behalf of itself and other similarly situated investors, filed a putative securities class action in the United States District Court for the Southern District of New York against the Company and certain of its executive officers, captioned Indiana Public Retirement System v. Inspire Medical Systems, Inc., et al., Case No. 1:25‑cv‑10620 (S.D.N.Y.) (the “Indiana PRS Lawsuit”). The Indiana PRS Lawsuit arises from the same underlying subject matter as the City of Pontiac Lawsuit. It alleges the same violations of law and is based on the same or similar purportedly materially false and misleading statements made during the same class period, all of which relate to the launch of the Company’s Inspire V neurostimulator. The plaintiffs seek, among other relief, unquantified compensatory damages, together with attorneys’ fees and costs. On January 22, 2026, the Company and the individual defendants moved to transfer the case to the United States District Court for the District of Minnesota. That motion remains pending. The Company and the individual defendants intend to vigorously defend against the action. No accrual for loss has been accrued or recorded in the Company’s financial statements as of, or for the period ended, December 31, 2025 since the Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
In addition, we are currently a party to multiple adversarial proceedings with Nyxoah regarding our patent portfolio and the patents of third parties. For additional information, see Note 11, Commitments and Contingencies to the
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for our Inspire system and our results of operations.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
In the course of conducting our business, we must adequately address quality issues that may arise with our Inspire system, including defects in third-party components included in our Inspire system. There can be no
Read it in 10-K Feb 13, 2026 at sec.gov
Show the other 62
AddedRisk Factors
We rely extensively on information technology systems to conduct our business and collect, store, process and transmit confidential and sensitive information, including personal information of (or relating to) customers, patients and our employees and contractors. These systems support, among other things, manufacturing and distribution, supply chain management, order processing, financial reporting, patients, regulatory and legal compliance and other critical business functions. Our information technology systems, operational technology environments, and those of our third-party service providers, vendors, contract manufacturers, strategic partners and other contractors or consultants are vulnerable to evolving cybersecurity threats. These threats include, but
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
are not limited to, damage or interruption from computer viruses and malware (e.g. ransomware), misconfigurations, “bugs” or other vulnerabilities, malicious code, terrorism, telecommunication and electrical failures, hacking, cyberattacks, phishing and other social engineering attacks, denial of service attacks, insider threats, human error, fraud, unauthorized access, and attacks by sophisticated nation-state and nation-state-supported actors. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
utilized and our federal R&D credit carryover was $10.1 million. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a change of ownership within the definition of Section 382 of the Code, we may not be able to utilize a material portion of the remaining R&D credit carryforwards, even if we sustain profitability.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedRisk Factors
Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.
Read it in 10-K Feb 13, 2026 at sec.gov
RemovedRisk Factors
Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. On December 22, 2023, we and certain of our executive officers were named in a putative class action lawsuit. The plaintiff filed an amended complaint on April 19, 2024, which alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5, which alleged violations relate to certain prior disclosures of Inspire about the effectiveness of a program intended to help certain customers establish independence in seeking prior authorization from payors for our Inspire therapy. The plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired Inspire common stock between May 3, 2023 and November 7, 2023. The plaintiff seeks damages and other relief, including attorneys' fees and costs. The defendants are vigorously defending this lawsuit. On June 28, 2024, the defendants moved to dismiss the amended complaint in its entirety. The motion was argued in November 2024.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
we may lose sales, experience manufacturing or other delays, incur increased costs or otherwise experience impairment to our customer relationships. We cannot guarantee that we will be able to establish alternative relationships on similar terms, without delay or at all.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
We rely extensively on information technology systems to conduct our business and collect, store and transmit confidential information, including personal information of customers and our employees and contractors. These systems affect, among other things, ordering and managing materials from suppliers, shipping products to customers, processing transactions, summarizing and reporting results of operations, patient marketing, complying with regulatory, legal or tax requirements, data security and other processes necessary to manage our business. Our information technology systems and those of our third-party service providers, vendors, strategic partners and other contractors or consultants are vulnerable to damage or interruption from computer viruses and malware (e.g. ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, malicious code, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
As we grow our international presence and global operations, we will have increasing obligations to comply with trade and economic sanctions and other restrictions imposed by the U.S., the EU, and other governments and organizations. During the year ended December 31, 2024, approximately 4.0% of our total sales were made in EU member states and certain Asia Pacific regions. The U.S. Departments of Justice, Commerce, State and Treasury
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
In the EU, both (i) devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May 26, 2021 and (ii) legacy devices lawfully placed on the market after May 26, 2021 in accordance with the transitional provisions of the EU Medical Devices Regulation may generally continue to be made available on the market or put into service, provided that the requirements of the transitional provisions are fulfilled. In particular,
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
devices, we may face additional regulatory enforcement action, including FDA or foreign regulatory authority warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
Similarly, the EU landscape concerning medical devices recently evolved, and continues to undergo legislative changes. On May 25, 2017, the EU Medical Devices Regulation entered into force, which repeals and replaces
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
are subject to or affected by new and/or existing privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
Some of our intellectual property rights depend on a licensing agreement with a third party, and our patent coverage includes protection provided by licensed patents. Many of these licensed patents are over ten years old and the standard life of a patent is 20 years from its initial filing date. If in the future we no longer have rights to one or more of these licensed patents, our patent coverage may be compromised, which in turn could affect our ability to protect our Inspire system or defend against competitors.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
Moreover, we may become party to future adversarial proceedings regarding our patent portfolio or the patents of third parties. Such proceedings could include supplemental examination or contested post-grant proceedings such as review, reexamination, inter partes review, interference or derivation proceedings before the USPTO and
Read it in 10-K Feb 10, 2025 at sec.gov
RewordedRisk Factors
We are subject to the FDA’s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA and foreign regulatory authorities when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. authorities.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
We are subject to In the FDA’s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA and foreign regulatory authorities when we receive or become aware of U.S., information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. injury must be reported to the FDA.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Specifically, this final rule, The WMSR, which replaced the FDA expects to go into effect on February 2, 2026, establishes FDA's former Quality System Regulation, sets forth the “Quality Management System Regulation,” or QMSR, which FDA's requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers or our third-party manufacturers may not be able to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for our Inspire system and our results of operations.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Our estimates and assumptions that support the view that our existing cash, cash equivalents, short-term investments and revenue will be sufficient to meet our capital requirements and fund our operations for at least 12 months. months may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Our locations, and those of our customers and suppliers, can be disrupted by droughts, extreme temperatures, fires, flooding and other climate change-related risks, as well as earthquakes, actions by utility providers, and other catastrophic events such as an actual or threatened public health emergency.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Many aspects of these proposals are unclear or undeveloped, and we We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our tax liabilities.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Although we believe that there could be a benefit to our business as a result of GLP-1s reducing the BMI of our prospective patients and increasing the number of eligible patients for our Inspire therapy, there can be no assurance of such benefit.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
The availability of the PTAB as a lower-cost, faster and potentially more potent tribunal for challenging patents could increase the likelihood that our own patents will be challenged, thereby increasing the uncertainties and costs of maintaining and enforcing them.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products, either of which could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedRisk Factors
Furthermore, the use of our Inspire system for indications other than those approved by the FDA, approved by any foreign regulatory authority or certified by a notified body, may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.
Read it in 10-K Feb 13, 2026 at sec.gov
Quiet changesRisk Factors
In recent years, the stock markets generally have experienced extreme significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies.
Read it in 10-K Feb 13, 2026 at sec.gov
Quiet changesRisk Factors
The FDA’s and foreign regulatory bodies' authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury adverse health consequences or death.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
Third-party payors require physicians and hospitals to identify the service for which they are seeking reimbursement by using Current Procedural Terminology (“CPT") codes, which are created and maintained by the American Medical Association. Our various generations of Inspire therapy have been billed under different codes and reimbursement approaches throughout our history. For example, the procedures performed to implant our Inspire IV device are described for billing purposes using Category I CPT code 64582. And for 2025, the procedures performed to implant our Inspire V device were described for billing purposes using Category I CPT code 64568. There are also other relevant CPT codes for revisions, explants and DISE.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
In November 2025, the final 2026 Medicare reimbursement payments were announced. There has been, and still is currently, confusion on the appropriate reimbursement and coding for our products from CMS and Medicare Administrative Contractors ("MACs"), as well as other payors and stakeholders in the overall reimbursement and coding process. Most recently, we received clarification regarding the coding that should be used for the Inspire V procedure. Currently, healthcare centers and physicians should bill the most recent healthcare policies, be it a Medicare Administrative Contractor (MACs) or a commercial payor, and based on this clarification, we believe the
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
code will transition to CPT code 64582 for the Inspire V procedure, including the use of a -52 modifier. To date, our top commercial payers by volume have all adopted the guidance of 64568 for coding and reimbursement of Inspire V. Confusion will remain until there is definitive and public guidance from various stakeholders and we have sufficient claims data that has been submitted and processed across payers. The resulting coding and reimbursement decisions may impact our business, financial condition and results of operations, in particular our future revenues. We continue to work with the relevant stakeholders to get specific and accurate direction for Inspire V coding, including the -52 modifier that we would expect to reduce the professional fee for Inspire V procedures under CPT code 64582 by approximately 10% to 50% of the base rate. In any case, we believe that a significant decrease in the professional fee resulting from use of the –52 modifier will likely influence physicians’ willingness to perform the Inspire V procedure and may limit the number of cases they choose to undertake. Beyond our short-term initiatives intended to minimize the actual reduction applied to the professional fee, as well as to drive consistency across the country, we are seeking a long-term solution, including the creation of a separate CPT code. There can be no guarantee as to the timing or outcome of the CPT code to be applied.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
We rely on third-party suppliers to manufacture our Inspire system and its components. Many of these suppliers are currently single source suppliers. Currently, all of our manufacturing is done in the U.S. and most components for our Inspire system are sourced in the U.S. We have experienced supply disruptions in the past.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
Since 2023, glucagon-like peptide 1 ("GLP-1s"), a class of drug indicated for diabetes and obesity, has continued to gain popularity as a weight-loss drug. In late 2024, tirzepatide (marketed as Zepbound), a GLP-1 injection which was FDA approved for weight loss in 2023, was also FDA approved for treatment of OSA in patients with obesity and moderate to severe OSA. If GLP-1s are used to treat OSA in an indication for which Inspire therapy is approved, demand for our Inspire system for patients with that indication could be reduced. OSA is a multifactorial disease with many independent factors including age, gender, weight, and neck circumference. Inspire is designed to address antero-posterior airway collapse, also known as tongue base collapse. In contrast, patients with a higher BMI are subject to a larger neck circumference and present predominantly with lateral-wall collapse.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
We recorded a total income tax benefit of $79.7 million for the year ended December 31, 2025 and $4.9 million of expense for the year ended December 31, 2024. The provision for income taxes for fiscal 2025 includes a deferred tax benefit of $88.8 million related to the release of the valuation allowance against our net deferred tax assets, partially offset by current income tax expense of $9.1 million, which reflects federal and state income tax liabilities that are not fully offset by NOLs and credits due to limitations on net operating loss carryforwards and credits under the Internal Revenue Code of 1986, as amended. We expect that we will record income tax expense in 2026 and beyond as we expect to continue to generate additional taxable income for the foreseeable future.
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
The primary objective of our investment activities is to preserve our capital for the purpose of funding operations while at the same time maximizing the income we receive from our investments without significantly increasing
Read it in 10-K Feb 13, 2026 at sec.gov
AddedMD&A
Prior to December 31, 2025, we maintained a full valuation allowance against all of our net deferred tax assets, and as a result we have historically not recorded an income tax benefit in the accompanying consolidated financial statements. This valuation allowance reflected our assessment of whether it is more likely than not that we would generate sufficient taxable income in the future to be able to utilize our deferred tax assets. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and negative evidence to estimate if sufficient future taxable income will be generated to realize our deferred tax assets, and we considered cumulative losses in recent years to be a significant type of negative evidence. As of December 31, 2025, we determined that it is more-likely-than-not that a majority of our federal and state deferred tax assets will be realized. As a result, we recorded a release of the valuation allowance associated with these deferred tax assets, which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than sufficient to realize our federal and state deferred tax assets, and we recorded a deferred income tax benefit in the amount of $88.8 million for the year ended December 31, 2025 (see Note 7 to our Consolidated Financial Statements included elsewhere in this Form 10-K). We utilize financial projections to support our net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our net deferred tax assets. Changes in our valuation allowance will result in a change to tax expense.
Read it in 10-K Feb 13, 2026 at sec.gov
RemovedMD&A
The procedures performed to implant, revise, or explant our Inspire IV device are described for billing purposes in the U.S. with Category I Current Procedural Terminology codes (64582, 64583, and 64584, respectively). A Category I code (42975) is also used for Drug-Induced Sleep Endoscopy ("DISE") to evaluate sleep disordered breathing, which may be a necessary procedure to determine which patients are appropriate for Inspire therapy. In November 2024, the final 2025 Medicare reimbursement payments were announced. The Medicare national average 2025 payment to implant our Inspire IV device in a hospital outpatient site of service is $30,474, an increase of 3% from the 2024 rate. The 2025 Medicare national average ASC reimbursement is $25,832, an increase of 4% from the 2024 rate. The 2025 Medicare national average physician reimbursement is $816 for implantation of a hypoglossal nerve stimulator, a 1% decrease over the 2024 payment. The reimbursement for the DISE procedure in the hospital setting is $1,724, a 7% increase over the prior year amount. In the ASC setting, the reimbursement for the DISE procedure is $792, a 714% increase from the 2024 amount. The 2025 Medicare national average physician reimbursement for the DISE procedure is $94, a 2% decrease over the prior year amount.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
We rely on third-party suppliers to manufacture our Inspire system and its components. Many of these suppliers are currently single source suppliers. We have experienced supply disruptions that began during the COVID-19 pandemic, but to date we have managed to avoid major delays in implant procedures due to those issues. During the third quarter of 2023, we experienced an inventory supply issue related to our polyurethane-based stimulation leads, one component of the Inspire system used only in the European market at that time. In 2022, the FDA approved our silicone-based stimulation and sensing leads in the U.S., which replaced the polyurethane versions of the leads, and we stopped manufacturing polyurethane leads. We applied for EU MDR certification in December 2021, which we received in July 2024, following industry-wide delays in the process. In the interim, we had received a derogation pursuant to Article 59 of the EU MDR from the Dutch, German, Swiss, Belgian, and Austrian competent authorities, and the British equivalent, i.e. exceptional use authorization, from the United Kingdom national competent authority, allowing us to continue to place the silicone-based leads on the market in those countries until various dates in 2024 or until we received certification under the EU MDR, whichever occurred first. Now that we have obtained certification under the EU MDR, silicone leads may be marketed throughout the EU. During the fourth quarter of 2023 and extending into early 2024, the delay in certification and the shortage of polyurethane-based stimulation leads caused delays to implant procedures which adversely affected our business in Europe, including a reduction in our European revenue, and thereby our consolidated revenue. We estimate the impact during the fourth quarter of 2023 was approximately $4.0 million in lost revenue opportunity, most of which we believe was recovered during the first half of 2024.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
Our products are shipped directly to our U.S. customers and to our Singapore and Hong Kong distributors on a purchase order basis, primarily by a third-party vendor with a facility in Tennessee, although we do ship some products from our facility in Minnesota. Warehousing and shipping operations for our European customers are handled by a third-party vendor with a facility located in the Netherlands, and warehousing and shipping operations for our Japanese customers are handled by a third-party with a facility in Japan. Customers do not have the right to return a non-defective product, nor do we place product on consignment. Our sales representatives do not maintain trunk stock.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
2023, we received approval from the FDA on an expanded indication which includes an increase on the upper limit of the Apnea Hypopnea Index to 100 events per hour from 65 and raises the Body Mass Index ("BMI") warning in the labeling to 40 from 32, and we also received FDA approval of our new physician programmer, called the SleepSync™ programmer, which we launched in the U.S. in late 2024. In March 2023, we received FDA approval to offer Inspire therapy to certain pediatric patients with Down syndrome.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
Our direct-to-consumer marketing program's goals are therapy awareness, connecting patients with providers, and supporting the patient through their path to Inspire from start to finish. Our investments in advertising are designed to increase patient awareness and encourage them to visit our website. On our website, patients can explore educational materials and videos about sleep apnea, learn about the benefits of Inspire therapy, find physician and clinical site contact information, and stay informed about community awareness events. We also use the Inspire Sleep app as a valuable tool for patient education. Moving forward, we plan to refine and optimize our outreach strategies, with an emphasis on expanding digital advertising efforts to reach more qualified patients. We generally expect to maintain our level of direct-to-consumer expenditures.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
We have a call center which we refer to as the Inspire Advisor Care Program. The primary purpose of this program is to assist patients with making a connection with a qualified healthcare provider based on their specific needs. In 2022, we initiated a digital scheduling program to facilitate and streamline patient access to care. We intend to continue to enhance this scheduling capability during 2025.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
We also continue to make significant investments to build our sales and marketing organization by increasing the number of U.S., European, and Japanese sales representatives and continuing our direct-to-consumer marketing efforts in existing and new markets. During 2024, we activated 285 U.S. centers bringing the total to 1,435 U.S. medical centers implanting Inspire therapy as of December 31, 2024. Additionally, we created 48 new U.S. sales territories during 2024, bringing the total to 335 U.S. territories as of December 31, 2024.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
recovery of most of the estimated $4.0 million of revenue opportunity from the fourth quarter of 2023. Other factors contributing to revenue growth were increased market penetration in existing centers, the expansion of our European sales representatives into new territories and centers, the start of reimbursed procedures in France, increased sales in the Asia Pacific region, and, we believe, increased physician and patient awareness of our Inspire system.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
We recorded a provision for income taxes of $4.9 million and $1.2 million for the years ended December 31, 2024 and 2023, respectively. This change was primarily due to an increase in state and local taxes.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
In August 2024, our Board of Directors authorized the repurchase of up to $150.0 million in our common stock through August 5, 2026 (the "Repurchase Program"). In November 2024, we entered into an accelerated share repurchase agreement (“ASR”) with a large financial institution as part of the Repurchase Program, whereupon we paid the counterparties to the ASR $75.0 million for the repurchase of shares of our common stock. In November 2024, we received an initial delivery of 305,157 shares of common stock representing a portion of the prepayment, which shares had an average price paid per share of $196.62. Upon final settlement of this ASR in January 2025, we received an incremental delivery of 103,886 shares of our common stock. Under this ASR, we repurchased a total of 409,043 shares at an average price paid per share of $190.29.
Read it in 10-K Feb 10, 2025 at sec.gov
RewordedMD&A
For the year ended December 31, 2024, 2025, we generated revenue of $912.0 million with a gross margin of 85.4% and net income of $145.4 million, compared to revenue of $802.8 million with a gross margin of 84.7% and net income of $53.5 million, compared to million for the year ended December 31, 2024, and revenue of $624.8 million with a gross margin of 84.5% and a net loss of $21.2 million for the year ended December 31, 2023, and revenue of $407.9 million with a gross margin of 83.8% and a net loss of $44.9 million for the year ended December 31, 2022. 2023.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
The remainder of the non-cash charges included accretion the recognition of investment discount due to higher investment balances, a deferred tax benefit, depreciation and amortization expense which increased with additional purchases of property and equipment, an impairment of a strategic investment, accretion of investment discount on our available-for-sale investments, a change in the benefit provision for estimated credit losses related primarily to accounts receivable with two healthcare systems, losses, and other non-cash expenses. other, net.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
The non-cash charges consisted primarily of stock-based compensation, which increased mainly as a result of the accelerated recognition of stock-based compensation expense for employees who are retirement eligible in accordance with implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement, and granting more equity awards to a greater number of employees as compared to the same prior year prior-year period.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Overall revenue Revenue growth in the U.S. was primarily due to increased market penetration in existing centers, expansion into new territories and centers, penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints. constraints and some patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Overall revenue growth was primarily due to increased market penetration in existing centers, expansion into new territories and centers, penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints. constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Other income, net increased decreased by $2.0 $7.6 million, or 9.8%, 34.1%, to $14.7 million of income for the year ended December 31, 2025 compared to $22.4 million of income for the year ended December 31, 2024 compared to $20.4 million of income for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Operating assets include inventories, which increased as supply chain constraints continued we continue to ease and build inventory on hand increased levels to support higher sales and the launch of our next generation Inspire system, V, and accounts receivable, which increased primarily due to the higher sales volume we typically experience late in the fourth quarter. which occurred during September 2025.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
See section titled “Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities” in Part II, Item 5 of this report for a discussion of our share repurchase program and related stock repurchases during the quarter ended December 31, 2024 and 2025 as well as Note 6 of our Notes 5 to our Consolidated Financial Statements for further details regarding our Repurchase Program. included elsewhere in this Form 10-K.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
This change was primarily due to an increase decrease of $2.7 $5.7 million in interest and dividend income due to higher lower cash, cash equivalents, and investment balances, an impairment charge of $4.0 million on one of our strategic investments, and an increase of $0.1 million in interest expense, partially offset by an increase in net losses of $0.7 $2.2 million in foreign currency translation and remeasurement gains due to exchange rates.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Based on our ongoing ADHERE patient registry, the average BMI of patients treated with Inspire therapy is 29 and the American Academy of Sleep Medicine guidelines recommend weight loss prior to surgery for patients with BMI over 35 and nonsurgical solutions for patients with BMI over 40. 29.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Net cash used in financing activities was $52.4 $183.4 million for 2024 2025 and consisted primarily of a $75.0 share repurchases of $175.0 million under our share repurchase authorizations and the payment for our ASR agreement and $5.2 of $23.0 million of taxes paid on net share settlement of equity awards, partially offset by proceeds from the exercise of stock options of $22.2 $9.6 million and proceeds from the issuance of common stock from our Employee Stock Purchase Plan ("ESPP") of $5.6 $5.0 million.
Read it in 10-K Feb 13, 2026 at sec.gov
RewordedMD&A
Cost of goods sold increased $26.4 $10.2 million, or 27.3%, 8.3%, to $133.2 million for the year ended December 31, 2025 compared to $123.0 million for the year ended December 31, 2024 compared to $96.6 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 13, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.